For most of human history, excess body fat was not a liability.
It was insurance.
In prehistoric environments shaped by famine and infection, natural selection favoured bodies that could store energy efficiently and release it slowly. These so called “thrifty” traits helped humans survive long periods with little food. It that context, the ability to gain and maintain weight was an advantage.
The problem is that human biology evolved far more slowly than the world around it.
As food became abundant and physical labour less essential, the same biological traits that once protected us began to work against us. Obesity emerged not as a moral failure, but as a predictable consequence of ancient biology colliding with modern environments.
Physicians began to recognise the consequence early. As far back as the 18th century, medical writers described links between excess weight and disease. By the 20th century, advances in endocrinology and genetics made the picture clearer: obesity is driven by a complex interplay of environment, hormones, metabolism, and genes – including pathways such as ghrelin and leptin signalling and the melanocortin system, which regulate appetite and energy balance.
Over time, it became undeniable that obesity is not just about body size. It is a systematic disease, affecting nearly every organ in the body and contributing to conditions ranging from diabetes, cardiovascular disease to cancer.
A long history of trying to lose weight
Efforts to treat obesity are nearly as old as its recognition.
One of the most striking historical anecdotes comes from 10th-century Spain, King Sancho I of León reportedly lost his throne in part because of his size. His “treatment” was extreme: his lips were sutured shut, and he was fed a liquid diet through a straw. He lost a significant amount of weight – and regained his crown.
Modern medical approaches emerged much later. In the mid-20th century, surgeons began experimenting with metabolic operations such as the jejunoileal bypass. These early procedures often produced dramatic weight loss, but at a cost of serious complications.
Across the following decades, surgical techniques evolved. Today’s bariatric procedures – most commonly Roux-en-Y gastric bypass and sleeve gastrectomy – are far safer and among the most effective long-term treatments for severe obesity.
Importantly, these operations do more than restrict food intake. They alter hormones, metabolism, and gut physiology in ways that lead to sustained weight loss and improvements in conditions such as type 2 diabetes, hypertension, and fatty liver disease.
But weight loss is only part of the story.
When obesity meets cancer
As research advanced, it became increasingly clear that the consequences of obesity extend well beyond cardiovascular and metabolic disease. Obesity is now linked to at least 13 different cancers, including those of the gastrointestinal tract – such as oesophageal, colorectal, liver, pancreatic, and gallbladder cancers.
These links are not incidental.
Chronic inflammation, insulin resistance, gastro-oesophageal reflux disease (GORD), and fatty liver disease all create biological environments that can promote cancer development over time.
If obesity increases cancer risk through these pathways, a natural question follows:
Can sustained weight loss reduce that risk?
And more specifically – can bariatric surgery, the most effective treatment for severe obesity, change the risk of upper gastrointestinal cancers?
That question led us to undertake a systematic review and meta-analysis.
What we set out to answer
Individual studies examining cancer risk after bariatric surgery have reported mixed results. Some suggest a protective effect, others show no clear association, and a few raise concerns about increased risk of specific cancers – particularly in the oesophagus.
We set out to bring this evidence together.
Our aim was to critically analyse all available studies comparing cancer incidence among people who had undergone bariatric surgery with similar individuals who had not, focusing specifically on cancers of the upper gastrointestinal tract.
What we studied
We identified 20 studies from around the world, including:
- More than 1.1 million individuals who had undergone bariatric surgery.
- Over 4.6 million comparison patients who were eligible for bariatric surgery but did not have it.
We examined the (post-surgery) incidence of:
- Oesophageal cancer
- Gastric (stomach) cancer
- Liver cancer
- Pancreatic cancer
- Gallbladder cancer
- Small intestinal cancer
- Biliary tract cancer
By pooling results across studies, we were able to generate more reliable and precise estimates than any single study alone.
What we found
A lower overall risk
Bariatric surgery was associated with a 42% lower risk of developing upper gastrointestinal cancers when they were all combined, compared with no surgery.
This pattern was consistent across different regions and across studies with both shorter- and longer-term follow-term.
Differences between cancer types
The picture became more nuanced when we looked at individual cancers.
Oesophageal cancer
Bariatric surgery was associated with a lower risk of oesophageal cancer, although results were not consistent across studies. Importantly, we did not find clear evidence that surgery increases risk. However, uncertainty remains. This is partly because different surgery types may have different effects on GORD – a key driver of oesophageal adenocarcinoma specifically. This means that, rather than a single uniform effect, the impact of surgery may vary depending on the procedure and the specific type of oesophageal cancer.
Liver cancer
We observed a clear and consistent reduction in risk – likely reflecting improvements in fatty liver disease and chronic inflammation following surgery.
Gallbladder cancer
Risk was also reduced, even though gallstones are more common after rapid weight loss.
Gastric and pancreatic cancers
We did not find any strong evidence of a protective effect.
For rarer cancers, such as those of the bile duct and small intestine, the available data were too limited to draw firm conclusions.
What might explain these changes?
Bariatric surgery triggers profound biological changes that extend far beyond weight loss alone.
This includes:
- Reduced chronic inflammation
- Improved insulin sensitivity
- Altered bile acid metabolism
- Changes in the gut hormones and the microbiome
- Regression of fatty liver disease
Many of these pathways are directly involved in cancer development. By improving the underlying metabolic environment, bariatric surgery may reduce the conditions that allow certain cancers to emerge over time.
This does not mean surgery eliminates cancer risk – or that it should be viewed as a treatment for cancer.
But it does mean that meaningful, sustained changes in metabolism could influence long-term disease risk in important ways.
Looking forward
Our findings suggest that, for some of the most serious obesity-related cancers, changing the metabolic environment through surgery may help tilt the odds towards healthier aging.
Future research will need to follow patients for longer, better compare different surgical procedures, and identify which patients benefit most.
But one message is already clear.
What once helped humans survive scarcity is now shaping disease in an age of abundance – and changing that biology may be key not just to weight loss, but to cancer prevention.